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There is an urgent medical need for improved vaccines with broad serovar coverage and
high efficacy against systemic salmonellosis. Subunit vaccines offer excellent safety pro-
files but require identification of protective antigens, which remains a challenging task.
Here, I review crucial properties of Salmonella antigens that might help to narrow down
the number of potential candidates from more than 4000 proteins encoded in Salmo-
nella genomes, to a more manageable number of 50–200 most promising antigens. I also
discuss complementary approaches for antigen identification and potential limitations of
current pre-clinical vaccine testing.
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INTRODUCTION
Salmonella enterica serovars Typhi and Paratyphi A, B, and C
cause human enteric fever with an estimated annual number
deaths of 190,000 (1). Enteric fever disease burden is proba-
bly underestimated because of difficult and insensitive diagnosis
methods (2). In addition to these serovars, specific strains of
serovar Typhimurium,which usually causes self-limiting gastroen-
teritis, can also cause systemic disease, particularly in young HIV-
infected children in sub-Saharan Africa (invasive non-typhoidal
salmonellosis, iNTS) (3).
Enteric fever and iNTS become increasingly difficult to treat
with antibiotics because of rising resistance to fluoroquinolones
and cephalosporins, and new drug candidates for these and
other Gram-negative pathogens are scarce suggesting a risk of an
increasing number of untreatable cases (2, 4).
THE NEED FOR NOVEL SUBUNIT VACCINES
Enteric fever can be prevented with a variety of vaccines (5). Killed
whole-cell preparations of serovars Typhi and Paratyphi were suc-
cessfully used to diminish incidence in endemic areas, but their
use was discontinued because of frequent adverse reactions (6).
A live attenuated S. Typhi strain Ty21a that was generated by
chemical mutagenesis confers a moderate level of protection for
up to three years against serovar Typhi, but not other relevant
serovars (6). Additional genetically modified Salmonella strains
have been tested in clinical trials with some success, but none
of them has yet reached approval. Finally, the purified capsu-
lar carbohydrate Vi of serovar Typhi induces protective immu-
nity over several years against serovars Typhi (6) and possibly
Paratyphi C, but not Paratyphi A and B or Typhimurium that
all lack such a capsule. Conjugation of Vi with an unrelated
protein antigen improves immune response in small infants, a
major target population for enteric fever (6). To cover the impor-
tant serovar Paratyphi A, current efforts focus on linking the O
antigen (carbohydrate part of lipopolysaccharide) with a protein
antigen (7).
In conclusion, treatment of systemic salmonellosis becomes
increasingly difficult, and prevention with currently available vac-
cines is hampered by only moderate levels and limited duration of
protection, and incomplete coverage of clinically relevant serovars.
This situation generates an urgent medical need for improved
Salmonella vaccines.
Live attenuated Salmonella strains offer important advantages
such as low production costs and oral administration, but pose a
risk of causing disease especially in immunocompromised patients
that might be inadvertently exposed, e.g., household contacts
of vaccines that shed live Salmonella. Whole-cell killed vaccines
are effective but contain pyogenic components that cause unac-
ceptable inflammatory responses. As a consequence, development
focuses on subunit vaccines that contain one or several key
antigens inducing protective immune responses.
The key challenge of developing such a vaccine is identi-
fication of suitable antigens. Unfortunately, among thousands
of potential Salmonella antigen candidates, probably only very
few have the necessary properties. Efficient strategies to iden-
tify protective antigens among large number of candidates have
been developed and applied for vaccines that protect against
extracellular pathogens using inhibitory/bactericidal antibodies
(reverse vaccinology) (8). For these pathogens, suitable anti-
gens need to be surface exposed to enable antibody bind-
ing, which substantially narrows down the number of poten-
tial candidates. Furthermore, immunization trials can be scored
for inhibitory/bactericidal antibodies using rather simple assays
amenable for high-throughput.
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In contrast, similar strategies have not yet been developed for
intracellular pathogens like Salmonella (which reside mostly in
host macrophages during systemic disease), since criteria for pre-
selecting promising antigens are unclear for most such pathogens,
and immune correlates of protection remain poorly character-
ized. Antibodies (or just B cells) often contribute to protection but
T cell responses are usually also required. The crucial αβ T cells
recognize peptide epitopes and this led to a focus on protein anti-
gens. Most intracellular pathogen genomes encode thousands of
proteins, and identification of the few protective antigens among
these numerous candidates remains challenging.
However, extensive recent work on Salmonella has uncovered
some information that might be useful as a rational basis for future
vaccine development against this and possibly other intracellular
pathogens. In particular, coverage of relevant Salmonella strains,
antigen expression in infected host tissues, and antigen compart-
mentalization within the Salmonella cell may substantially narrow
down the number of promising antigen candidates.
ANTIGENS ENABLING BROAD SEROVAR COVERAGE
To achieve protective immunity against all relevant Salmonella
strains, conserved antigens must be used. Hundreds of genes are
missing or dysfunctional due to frameshift mutations or prema-
ture stop codons in certain relevant strains (9), but the rapidly
increasing collection of genome sequences facilitates identifica-
tion of suitable broadly conserved antigens. Orthologs usually
share extensive sequence identity, but rare non-synonymous point
mutations might still affect potentially crucial immunity determi-
nants such as surface-exposed loops of outer membrane proteins
(10). The 3D structures of many Salmonella proteins have been
determined, and additional structures can be modeled based on
homologs. However, it remains challenging to estimate which
amino acid differences might impair cross-protective immune
responses. As a consequence, antigens with highly conserved
sequence among relevant serovars might be prioritized. On the
other hand, antigens that play a potentially crucial role in patho-
genesis of only a subset of serovars such as typhoid toxin (11)
could still be an important contributor to vaccine combinations
containing multiple antigens.
ANTIGEN EXPRESSION IN HOST TISSUES
To detect and kill Salmonella, the immune system must recognize
antigens that Salmonella expresses in infected host tissues. For
animal infection models, purification of genetically engineered
fluorescent Salmonella cells from infected tissue homogenates
using flow cytometry yields sufficient material for large-scale pro-
teome analysis (12, 13). The results reveal expression of more than
1800 Salmonella antigens in mouse spleen. As a caveat, this analy-
sis misses most secreted Salmonella proteins that are lost during
purification. This is important, since at least one secreted protein
can confer moderate protection (14). While escaping proteomics
of purified Salmonella, highly expressed secreted proteins can be
identified based on transcriptional in vivo data (15, 16).
Recent advances in proteomics enable even absolute quantifi-
cation of copy numbers per Salmonella cell for most detected anti-
gens (10). High expression levels might facilitate immune recog-
nition (10, 15), but our systematic analysis did not support that
protective antigens are generally highly expressed (10). This could
reflect extensive host–pathogen coevolution modulating expres-
sion levels and immunogenicity of antigens. However, despite
the poor predictive power of quantitative expression levels, anti-
gen expression itself remains a crucial precondition for protective
immune responses.
Salmonella proteomes in human tissues have not yet been inves-
tigated. However, experimental infections of human volunteers
have been done in the past (17, 18), and a well-controlled protocol
has recently been established (19). Purification by flow cytometry
similar to the mouse studies would require infection with a geneti-
cally modified Salmonella strain, and type and required quantities
of biopsy material would need to be determined.
Salmonella virulence has been extensively characterized in the
mouse typhoid fever model. These studies have identified more
than 270 Salmonella genes that contribute to pathogenesis. In
almost all cases, this evidence indicates expression of the respective
antigens at least at some stage of the infection. Virulence pheno-
types in human beings are also available in a few cases from vaccine
trials with live attenuated Salmonella strains (20–22). These scarce
human data are largely consistent with observations for the corre-
sponding Salmonella mutants in the mouse model, but systematic
comparisons are currently impossible due to the lack of human
data for most potential virulence factors.
Using another indirect approach, large-scale studies have iden-
tified antibodies that specifically recognize dozens of Salmonella
antigens in sera of acutely infected and convalescent patients or
experimentally infected mice, but not uninfected controls (23,
24). The presence of such antibodies is a clear indication that
the respective Salmonella antigens are expressed at least at some
stages of infection. Interestingly, there is a considerable overlap in
immune signature of murine and human salmonellosis. On the
other hand, comparison with direct ex vivo proteome analysis of
Salmonella purified from infected mouse spleen reveals that serum
antibodies recognize only a small minority of the more than 1800
in vivo expressed Salmonella antigens. It is possible, that Salmonella
antigens that induce specific antibodies are particularly accessible
for the host immune system, and thus represent most promis-
ing vaccine antigen candidates. However, direct comparison of
antibody titers in convalescent mice with antigen protectivity in
immunization/challenge studies shows that serum antibody lev-
els have poor predictive power for identifying suitable vaccine
antigens (10, 23). In fact, several of the most protective vaccine
antigens failed to elicit detectable antibody responses in both mice
and human beings, while immunodominant antigens mostly fail
to protect.
Similar to antibody response in convalescent individuals, T
cell responses to specific Salmonella antigens provide information
about antigen expression during infection. CD4 T cell epitopes
have been comprehensively predicted based on peptide properties
that facilitate binding to antigen-presenting major histocompati-
bility complex (MHC) II molecules and T cell receptors (25). Some
antigens were experimentally confirmed to be recognized by T cells
from infected human beings (26, 27) and mice (14, 25, 28, 29), but
not uninfected individuals. These results confirmed expression
of corresponding Salmonella antigens (including the promising
antigen SseB) at least during some stages of infection. Again, these
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identified antigens are only a small subset of all expressed antigens,
and T cell responses during infection have poor predictive power
for protective antigens (10). This might reflect expression at infec-
tion stages (29) or in distinct tissue microenvironments (30) that
have limited relevance for protective immunity.
In conclusion, proteomics and virulence phenotypes pro-
vide large-scale information on Salmonella antigen expression in
infected mice. Together, some 2000 different Salmonella antigens
are expressed during infection in the mouse typhoid fever model,
and might thus represent potential vaccine antigens. Evidence for
human infections is much more fragmentary and largely restricted
to serum antibody and T cell responses.
ANTIGEN COMPARTIMENTALIZATION
The localization of an antigen within the Salmonella cell may have
a major impact on its protectivity. In particular, live intact Salmo-
nella can only be detected by the host immune system through
recognition of surface-exposed/released antigens, since internal
Salmonella antigens are shielded by the cell envelope. On the other
hand, dead Salmonella might release antigens regardless of their
initial localization. In many infection foci, live and dead Salmonella
reside in close proximity (30), and recognition of dead Salmonella
alone might be sufficient for activation of bystander cells contain-
ing live Salmonella, resulting in effective clearance of both live and
dead Salmonella. However, a subset of live Salmonella resides in tis-
sue regions without any dead Salmonella (10, 30), and these would
escape detection/clearance by immune responses directed exclu-
sively against internal Salmonella antigens. This working model
is supported by previously identified protective antigens (15, 31–
33) and our systematic comparison of Salmonella antigens from
different compartments (10): all identified protective antigens are
surface exposed. A recent study extended this finding to a secreted
virulence effector protein (14), supporting the hypothesis that
antigens must be accessible on live Salmonella to confer protective
immunity.
Surface exposure/secretion might represent a powerful cri-
terion to narrow down the number of potentially promising
Salmonella vaccine antigens. Surface-exposed outer membrane
proteins can be identified based on primary sequence proper-
ties and have been tabulated in databases (34, 35). Interestingly,
outer membrane-associated lipoproteins can also confer protective
immunity, even when they likely localize to the shielded periplas-
mic side of the outer membrane (10). Possibly, such lipoproteins
are released in outer membrane vesicles that are degraded in
host cell lysosomes thus exposing lipoproteins to the antigen-
presentation platforms. Outer membrane-associated lipoproteins
can again be identified based on primary sequences (36). Experi-
mental analysis of outer membrane preparations (37, 38) and/or
biotinylated surface-exposed proteins (39) can be used to confirm
theoretical predictions, and to identify additional exposed antigens
that might be secreted through unconventional mechanisms.
In addition to surface-associated proteins, Salmonella translo-
cates various proteins directly to the infected host cell cytosol,
predominantly using the SPI-2 associated type III secretion system.
SPI-2 effector proteins are intensively studied and the currently
identified list of 32 proteins (40) might approximate comple-
tion. The SPI-2 translocon subunit SseB itself is one of the most
promising vaccine antigens (15, 23, 27). During initial phases of
infection, Salmonella secretes proteins also through the SPI-1 asso-
ciated type III secretion system and through the flagellar apparatus
(in particular, flagellin, a moderately protective antigen) (29, 31).
Together, surface-exposed and secreted Salmonella antigens
comprise some 200 different antigens, and at least around 50 of
them are expressed during infection in the mouse typhoid model
based on transcriptional data, proteomics, virulence phenotypes,
and/or immunization data. Twenty-six such antigens have already
been tested and nine appear to confer some degree of protective
immunity in mouse typhoid fever immunization/challenge stud-
ies (FliC, SseB, OmpD, CirA, IroN, T0937, SlyB, PagN, and SseI; in
some cases group sizes were too small to obtain definitive proof)
(10, 14, 15, 29, 31–33).
FUTURE PERSPECTIVES
Immunization/challenge experiments in the mouse typhoid fever
model have shown that live attenuated Salmonella strains can pro-
vide full long-term protection against otherwise lethal challenge
infections (41). Compared to this benchmark, progress with sub-
unit vaccines in the same model has been somewhat disappoint-
ing. Despite large-scale experimental and computational screening
campaigns in several different laboratories, few Salmonella anti-
gens with at most moderate protectivity in the mouse typhoid fever
model have been identified. None of these antigens confer full pro-
tection for more than some 30 days after challenge infection. This
could reflect immune evasion of the challenge Salmonella strain by
mutation of crucial epitopes within the respective antigens. Dur-
ing such a long infection time, other adaptive immune responses
might be expected, but these responses are obviously insufficient
for protective immunity.
It is possible that the best protective antigens have not yet been
identified, or that multiple antigens need to be combined for full
protection and prevention of immune evasion. It is also possible
that antigens other than proteins, such as lipids, carbohydrates,
or even small molecules (42), are necessary for high levels of
protection. One approach to test this hypothesis could use progres-
sive depletion of specific antigens from protective live attenuated
Salmonella strains, by deleting respective biosynthesis genes. How-
ever, this approach is limited to non-essential genes and is thus
non-informative for antigens such as riboflavin intermediates (12,
42). Alternatively, killed whole-cell vaccines might be fractionated
and tested for protection. Unfortunately, killed whole-cell vaccine
formulations with high protective efficacy in the mouse typhoid
fever model have not yet been described. Future studies might
revisit this issue, especially since killed whole-cell vaccines confer
substantial protective immunity against invasive salmonellosis in
human beings (although they are no longer used because of severe
adverse reactions) (1).
Finally, it is important to consider what level of protection is
actually needed in pre-clinical mouse models before proceeding to
human clinical vaccine trials. In the typhoid fever model, genet-
ically high-susceptible mouse strains defective for the divalent
cation transporter Slc11a1 (NRAMP1) (43),are infected with doses
of S. enterica serovar Typhimurium that result in an attack rate of
100%. This combination reproduces some important aspects of
human disease including Salmonella dissemination from intestinal
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sites, histopathology in spleen and liver (splenomegaly, forma-
tion of structured inflammatory lesions), relevance of various
Salmonella virulence factors and host cytokines, and protective
immunity against reinfection in convalescent individuals, or indi-
viduals vaccinated with live attenuated Salmonella strains (41).
On the other hand, disease progression in mice is more rapid
and always lethal when using wild-type Salmonella strains, in
contrast to human enteric fever. Importantly, protective immu-
nity against challenge infections in the mouse model requires
both B cell and CD4 T cell responses (28), but neither anti-
bodies (44) nor MHC I-restricted CD8 T cells (45). In contrast,
vaccination-induced antibodies alone seem to confer already a
substantial level of protection in human beings (46), at least in
endemic areas where pre-existing immune responses to Salmonella
are highly prevalent (24). It is thus possible that full protection
against virulent wild-type Salmonella strains in genetically sus-
ceptible mice might be too stringent a criterion to judge vaccine
efficacy.
Instead, it might be worth considering genetically resistant mice
(47), in which antibodies seem to suffice for protective immunity
(48), and heat-killed Salmonella mediate substantial immunity
(49) similar to the situation in human beings (6). Interestingly,
flagellin is also highly protective in resistant mice (50), in contrast
to only moderate protectivity in susceptible mice.
In addition to the mouse strain, the challenge infection dose
should be re-considered. Controlled human trials have shown
that vaccine-induced immunity can be easily overwhelmed by
even moderate challenge doses (17). Vaccines that have well-
documented efficacy in field-trials, completely fail to protect
against S. Typhi when given at doses in the range of 106–107 CFU.
Vaccine efficacy is only seen at a much lower dose of 105 CFU that
caused disease in only 40% of unvaccinated control volunteers [a
recent study showed higher attack rates at such doses (19)]. Based
on these human data, commonly used mouse challenge infections
that result in 100% attack rates might be too stringent for reveal-
ing a moderate level of protective immunity that could still be
sufficient for preventing even a large proportion of human disease
under relevant field conditions.
Finally, a better understanding of human immune responses
that are relevant for protective immunity could help to replace
the crude readout parameter “survival after challenge infection”
with more informative quantitative immune parameters. Ongo-
ing studies in an experimental human infection and vaccination
model (19) will likely provide such crucial information in the near
future.
CONCLUSION
Several Salmonella antigens that can mediate at least partial pro-
tective immunity against lethal challenge infections in mice have
recently been identified. Analysis of their properties suggests that
efforts to identify further suitable antigens might focus on a limited
number of promising surface-associated/secreted candidates that
are expressed in infected host tissues. However, none of the known
individual antigens mediates solid strong protection, comparable
to what can be achieved with attenuated live Salmonella strains.
Future studies could explore antigen combinations and possibly
antigens other than proteins. Moreover, a better understanding of
qualitative and quantitative immune parameters that are required
to protect human beings is needed to guide pre-clinical models
for further vaccine optimization and to determine what levels of
protection are needed.
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